NYSE · PRGO

PERRIGO COMPANY PLC

$10.14 +$0.05 (+0.50%) 1D After hours

Key Metrics

$1.40B
Market cap
P/E · TTM
$4.18B
Revenue · TTM
−$1.82B
Net income
EPS · TTM $-13.20
Dividend yield 11.4%
Free cash flow $107.70M
Beta · 1Y 1.09
EBITDA · TTM −$1.37B
Gross margin 34.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    The stock moved +10.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 16
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 31
    The stock moved +10.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31
  • Mar 20
    From its Feb 20 high, the share price fell 38%.

    Peak close $14.97 on Feb 20; trough close $9.25 on Mar 20. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -38%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.40B
Enterprise value
Shares outstanding138.4M
52-wk range$9.23 – $28.22
Avg volume · 20D1.7M
Net cash
Book value / share$18.15
IndustryPharmaceutical Preparations
ExchangeNYSE
About PERRIGO COMPANY PLC
IPO dateDec 16, 1991
Employees8100

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.33
P/FCF12.96
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 34.2%
Operating -41.0%
Net -43.5%
FCF 2.6%
ROE / ROIC -53.3% · —

Financial Health

Current ratio2.72
Quick ratio1.59
Debt / equity1.45
Debt / EBITDA -2.64
Net cash
Working capital$1.71B

Cash Flow · TTM

Operating CF $189.40M
Capex −$81.70M
Free cash flow $107.70M
Buybacks
Dividends paid $158.60M
Shareholder yield 11.4%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-0.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-28 · computed by TickerWolf from SEC filings